Unknown

Dataset Information

0

Preclinical Activity of Embryonic Annexin A2-Specific Chimeric Antigen Receptor T Cells Against Ovarian Cancer.

ABSTRACT: Chimeric antigen receptors (CARs) have found clinical success in B cell malignancies, but a dearth of potential targets limits their wider clinical application, especially in solid tumours. Here, we describe the development of an anti-annexin A2 CAR, CAR(2448), derived from an antibody found to have activity against epithelial ovarian cancer cell lines. The spacer length of CAR(2448) was optimised based on in vitro cytotoxic activity against ovarian cancer (OC) cell lines via a real-time cytotoxicity assay. The longer spacer CAR(2448)L T cells exhibit significant effector activity, inducing inflammatory cytokine release and cytotoxicity against OC cell lines. Furthermore, CAR(2448)L-BBz T cells induced enhanced survival in an in vivo OC xenograft model and reduced tumour volume by 76.6%. Our preclinical studies of CAR(2448) suggest its potential for the unmet need of novel strategies for the treatment of ovarian cancer.

SUBMITTER: Leong L 

PROVIDER: S-EPMC7013580 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Preclinical Activity of Embryonic Annexin A2-Specific Chimeric Antigen Receptor T Cells Against Ovarian Cancer.

Leong Leonard L   Tan Heng Liang HL   Cua Simeon S   Yong Kylie Su Mei KSM   Chen Qingfeng Q   Choo Andre A  

International journal of molecular sciences 20200107 2

Chimeric antigen receptors (CARs) have found clinical success in B cell malignancies, but a dearth of potential targets limits their wider clinical application, especially in solid tumours. Here, we describe the development of an anti-annexin A2 CAR, CAR(2448), derived from an antibody found to have activity against epithelial ovarian cancer cell lines. The spacer length of CAR(2448) was optimised based on in vitro cytotoxic activity against ovarian cancer (OC) cell lines via a real-time cytotox  ...[more]

Similar Datasets

Unknown CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.
| S-EPMC4644600 | biostudies-literature
Unknown Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma.
| S-EPMC7776337 | biostudies-literature
Unknown Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions.
| S-EPMC5759780 | biostudies-literature
Unknown Preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplantation.
| S-EPMC10113151 | biostudies-literature
Unknown TCRvβ8 chimeric antigen receptor natural killer cells exhibit potent preclinical activity against T-cell malignancies.
| S-EPMC11343688 | biostudies-literature
Unknown Humanized CD30-Targeted Chimeric Antigen Receptor T Cells Exhibit Potent Preclinical Activity Against Hodgkin's Lymphoma Cells.
| S-EPMC8790321 | biostudies-literature
Unknown Targeting of embryonic annexin A2 expressed on ovarian and breast cancer by the novel monoclonal antibody 2448.
| S-EPMC5862572 | biostudies-literature
Unknown L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice.
| S-EPMC4711972 | biostudies-literature
Unknown RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery.
| S-EPMC5426907 | biostudies-literature
Unknown Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.
| S-EPMC2747302 | biostudies-literature